Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of four new additions to the senior management team. As Actinium’s drug candidates continue to advance through the clinic, these hires are timely and expected to enable the Company to maximize the value of its assets. Capabilities are being added in clinical operations, regulatory affairs, quality assurance, finance and communications.
Help employers find you! Check out all the jobs and post your resume.
